ArticleCureus2026
Clinical Characteristics, Complications, and Post-stent Survival in Patients Undergoing Palliative Oesophageal Stenting: A Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose This study described post-stent survival and complication profiles in patients undergoing palliative oesophageal stenting for malignant dysphagia, to inform patient counselling. Methods An institutional audit reviewed palliative oesophageal stent insertions at Cambridge University Hospital (Apr 2020-Apr 2024). Patient demographics, complications, and survival were analyzed using SPSS (IBM Corp., Armonk, NY, USA) and Kaplan-Meier methods. Results Among 110 patients, 60.9% male (n=67); mean age 74.1 years, 95% CI 72.1-76.1), 93.6% (n=103) were deceased. Adenocarcinoma (n=68; 61.8%) and squamous cell carcinoma (n=32; 29.1%) were the most common histological subtypes, with tumours predominantly located in the lower and middle oesophagus. Thirty-six percent (n=39) received both chemotherapy and radiotherapy. Complications were stent migration (n=13;11.8%) and stent blockage (n=10;9.1%). Median post-stent survival was 162 days for squamous cell carcinoma, 97 days for adenocarcinoma, and 74 days for other types (log-rank p = 0.008); but did not differ significantly by tumour location (log-rank p = 0.73). In multivariable analysis, increasing age was associated with shorter post-stent survival (HR 1.05 per year, p = 0.001), while squamous cell carcinoma was associated with longer post-stent survival (HR 0.64, p = 0.037). Other variables were not independently associated with survival. Conclusion Palliative oesophageal stenting alleviates malignant dysphagia symptoms and has a known complication profile. Post-stent survival is linked to patient and tumour traits, underscoring its supportive role in prognostic counselling and post-procedure management. Implications for cancer survivors The findings highlight the role of oesophageal stenting in symptom relief rather than disease modification and may assist patients and clinicians in setting realistic expectations regarding prognosis and post-procedure care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.